Globus Medical, Inc.
NYSE:GMEDMedical - Devices
-$2.10 today
- Market cap
- $9.34B
- Beta
- 0.95
- P/E (TTM)
- 17.4
- EPS (TTM)
- $4.33
Volume 1.43M
Average 1.45M
GMED EBITDA Margin
EBITDA as a percentage of revenue.
Globus Medical, Inc.NYSE: GMED
EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026
EBITDA Margin widens to 32.8%
EBITDA Margin was 32.8% in Q2 FY2026, up 6.9 pp from a year earlier. On a trailing-twelve-month basis it was 30.1%, up 6.5 pp year over year. Over 3 fiscal years it widened by 0.4 pp.
Context
- EBITDA Margin widened in 1 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 11 analysts of 35.2% for the fiscal year ending Dec 2026, up from 30.2% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- 32.8%+3.0 pp QoQ
- Last fiscal yearDec 2025
- 30.2%+11.4 pp YoY
- LTMJun 2026
- 30.1%+6.5 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +6.9 pp | +6.0 pp | -0.8 pp |
| 1 year | +11.4 pp | +5.0 pp | -6.3 pp |
| 3 years | +0.4 pp | +4.7 pp | +4.2 pp |
| 5 years | +4.1 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 30.2%
- Year-over-year change
- +11.4pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 30.2% | +11.4pp |
| FY2024 | 2024-12-31 | 18.8% | -3.3pp |
| FY2023 | 2023-12-31 | 22.1% | -7.7pp |
| FY2022 | 2022-12-31 | 29.8% | +2.1pp |
| FY2021 | 2021-12-31 | 27.6% | — |
EBITDA Margin vs competitors
How GMED compares with its peers on the latest reported figures
- GMED's LTM Jun 2026 EBITDA Margin of 30.1% is the highest of the 10 companies compared; the peer median is 11.5%.
- Its year-over-year change of +6.5 pp is the 6th highest of 10, against a peer median of +7.7 pp.
- Over three fiscal years its change of +0.4 pp compares with a peer median of +5.4 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 30.1% | +6.5 pp | +0.4 pp | |
| LTM Jun 2026 | 27.5% | -1.6 pp | +5.4 pp | |
| LTM Jun 2026 | 25.9% | +5.9 pp | +3.4 pp | |
| FY2025 | 21.7% | -1.3 pp | -0.4 pp | |
| LTM Mar 2026 | 17.9% | +11.6 pp | +41.2 pp | |
| LTM Mar 2026 | 11.5% | +13.4 pp | -6.1 pp | |
| LTM Mar 2026 | 9.7% | +12.3 pp | +21.2 pp | |
| LTM Mar 2026 | -0.2% | +8.0 pp | +24.0 pp | |
| LTM Mar 2026 | -2.7% | +3.5 pp | +2.1 pp | |
| LTM Mar 2026 | -2.9% | +7.7 pp | +46.2 pp | |
| Peer median (excluding GMED) | 11.5% | +7.7 pp | +5.4 pp | |
Competitors are the stored peer set for GMED. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 958.1M | 1.02B | 1.57B | 2.52B | 2.94B |
| Cost of Revenue | 239.22M | 263.73M | 548.17M | 1.04B | 957.8M |
| Gross Profit | 718.88M | 759.12M | 1.02B | 1.48B | 1.98B |
| Gross Margin | 75.0% | 74.2% | 65.1% | 58.9% | 67.4% |
| Research & Development | 97.35M | 73.02M | 124.01M | 163.75M | 185M |
| Selling, General & Admin | 408.15M | 432.12M | 643.41M | 981.05M | 1.32B |
| Operating Expenses | 546.93M | 531.17M | 887.16M | 1.32B | 1.5B |
| Depreciation & Amortization | 69.87M | 68.25M | 144.73M | 254.02M | 276.84M |
| EBITDA | 264.73M | 304.5M | 346.58M | 473.73M | 886.74M |
| EBITDA Margin | 27.6% | 29.8% | 22.1% | 18.8% | 30.2% |
| Operating Income | 171.95M | 227.95M | 133.14M | 165.99M | 479.8M |
| Operating Margin | 17.9% | 22.3% | 8.5% | 6.6% | 16.3% |
| Interest Income | 9.3M | 14.23M | 20.13M | 0 | 7.14M |
| Interest Expense | 0 | 0 | 0 | 4.19M | 0 |
| Other Income / Expenses | 8.45M | 15.07M | 32.25M | (45.27M) | 130.1M |
| Income Before Tax | 180.41M | 243.02M | 165.39M | 120.72M | 609.9M |
| Pre-Tax Margin | 18.8% | 23.8% | 10.5% | 4.8% | 20.8% |
| Income Tax Expense | 31.22M | 52.85M | 42.52M | 17.74M | 72M |
| Net Income | 149.19M | 190.17M | 122.87M | 102.98M | 537.9M |
| Net Margin | 15.6% | 18.6% | 7.8% | 4.1% | 18.3% |
| EPS (Basic) | 1.48 | 1.89 | 1.09 | 0.76 | 3.98 |
| EPS (Diluted) | 1.44 | 1.85 | 1.07 | 0.75 | 3.92 |
| Weighted Avg Shares | 100.73M | 100.47M | 113.09M | 135.73M | 135.15M |
| Weighted Avg Shares (Diluted) | 103.62M | 102.64M | 114.63M | 137.86M | 137.22M |
Globus Medical, Inc.
NYSE:GMED
Intrinsic Alpha fair value
Locked
Current Price
$70.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.